• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pelthos Therapeutics Inc. Common Stock (NY:PTHS)

    22.25 -1.83 (-7.60%)
    Streaming Delayed Price Updated: 1:24 PM EDT, Mar 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pelthos Therapeutics Inc. Common Stock

    Pelthos Therapeutics Inc. (PTHS) Reports Strong Q4 2025 Earnings Beat Amid Muted Market Reaction ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
    From Horizon Technology Finance Corporation
    Via Business Wire
    News headline image
    Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
    Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
    Via Investor's Business Daily
    News headline image
    Pelthos Therapeutics Inc (NYSEARCA:PTHS) Stock Rises on Strong Q3 Revenue Beat ↗
    Pelthos Therapeutics (PTHS) Q3 2025 results show a huge 66% revenue beat driven by strong demand for its new product ZELSUVMI, despite a significant EPS loss. 
    Via Chartmill
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
     
    Via Benzinga
    News headline image
    EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗
    Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings. 
    Via Benzinga
    News headline image
    Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts ↗
    The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones. 
    Via Stocktwits
    Topics Government
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗
    Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.